GoodRx Holdings Management
Management criteria checks 2/4
GoodRx Holdings' CEO is Scott Wagner, appointed in Apr 2023, has a tenure of 1.67 years. total yearly compensation is $10.14M, comprised of 5% salary and 95% bonuses, including company stock and options. directly owns 0.12% of the company’s shares, worth $2.10M. The average tenure of the management team and the board of directors is 2.6 years and 7.3 years respectively.
Key information
Scott Wagner
Chief executive officer
US$10.1m
Total compensation
| CEO salary percentage | 5.0% |
| CEO tenure | 1.7yrs |
| CEO ownership | 0.1% |
| Management average tenure | 2.6yrs |
| Board average tenure | 7.3yrs |
Recent management updates
Recent updates
Capital Allocation Trends At GoodRx Holdings (NASDAQ:GDRX) Aren't Ideal
Dec 21
GoodRx Holdings, Inc.'s (NASDAQ:GDRX) Shares May Have Run Too Fast Too Soon
Oct 29GoodRx: The Tide Is Turning The Wrong Way (Rating Downgrade)
Oct 26GoodRx Holdings: Failing To Gain Much Traction
Oct 08GoodRx Holdings' (NASDAQ:GDRX) Returns On Capital Not Reflecting Well On The Business
Sep 22GoodRx Q2 Earnings Preview
Jul 31GoodRx Holdings (NASDAQ:GDRX) Could Easily Take On More Debt
Jul 12GoodRx Holdings, Inc.'s (NASDAQ:GDRX) 30% Price Boost Is Out Of Tune With Revenues
Jun 09Returns On Capital At GoodRx Holdings (NASDAQ:GDRX) Paint A Concerning Picture
Jun 06GoodRx: Encouraging Profit Stabilization (Rating Upgrade)
May 28GoodRx Holdings: Large TAM Continues To Support Growth
Mar 20GoodRx Holdings, Inc. (NASDAQ:GDRX) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Mar 07Is GoodRx Holdings, Inc. (NASDAQ:GDRX) Trading At A 24% Discount?
Mar 01GoodRx Holdings (NASDAQ:GDRX) Has A Rock Solid Balance Sheet
Feb 12GoodRx: Cost Saving Is A Strong Value Proposition To Consumers
Jan 23GoodRx Holdings (NASDAQ:GDRX) May Have Issues Allocating Its Capital
Jan 22GoodRx Stock Spikes After Receiving A Strong Dose Of Performance
Jan 11What Is GoodRx Holdings, Inc.'s (NASDAQ:GDRX) Share Price Doing?
Dec 02GoodRx Holdings (NASDAQ:GDRX) May Have Issues Allocating Its Capital
Sep 12An Intrinsic Calculation For GoodRx Holdings, Inc. (NASDAQ:GDRX) Suggests It's 41% Undervalued
Jul 14GoodRx Holdings' (NASDAQ:GDRX) Returns On Capital Not Reflecting Well On The Business
May 27Some Confidence Is Lacking In GoodRx Holdings, Inc. (NASDAQ:GDRX) As Shares Slide 27%
May 05Investors Give GoodRx Holdings, Inc. (NASDAQ:GDRX) Shares A 27% Hiding
May 05Is There An Opportunity With GoodRx Holdings, Inc.'s (NASDAQ:GDRX) 45% Undervaluation?
Mar 23GoodRx Holdings (NASDAQ:GDRX) May Have Issues Allocating Its Capital
Feb 07CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$16m |
| Jun 30 2024 | n/a | n/a | -US$59m |
| Mar 31 2024 | n/a | n/a | -US$7m |
| Dec 31 2023 | US$10m | US$512k | -US$9m |
Compensation vs Market: Scott's total compensation ($USD10.14M) is above average for companies of similar size in the US market ($USD5.54M).
Compensation vs Earnings: Insufficient data to compare Scott's compensation with company performance.
CEO
Scott Wagner (53 yo)
1.7yrs
Tenure
US$10,144,526
Compensation
Mr. Scott W. Wagner serves as Interim Chief Executive Officer at GoodRx Holdings, Inc. since April 25, 2023 and serves as its Principal Operating Officer since February 15, 2024. He serves as Head of Strat...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-founder & Chairman of the Board | 13.3yrs | US$811.53k | 1.4% $ 23.9m | |
| Interim CEO & Principal Operating Officer | 1.7yrs | US$10.14m | 0.12% $ 2.1m | |
| Co-founder | 13.3yrs | US$784.86k | 1.4% $ 23.9m | |
| Chief Financial Officer | 4.8yrs | US$902.24k | 0.079% $ 1.3m | |
| Chief Accounting Officer | 2.7yrs | US$2.58m | 0.024% $ 401.5k | |
| President of Healthcare | 4.5yrs | US$4.91m | 0.065% $ 1.1m | |
| President & Executive VP of Prescription Marketplace | less than a year | no data | no data | |
| Chief Technology Officer | 2yrs | no data | no data | |
| Director of Investor Relations | no data | no data | no data | |
| General Counsel & Secretary | no data | no data | no data | |
| Chief Marketing Officer | 1.4yrs | US$864.80k | no data | |
| Chief People Officer | 2.6yrs | no data | no data |
2.6yrs
Average Tenure
53yo
Average Age
Experienced Management: GDRX's management team is considered experienced (2.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-founder & Chairman of the Board | 13.3yrs | US$811.53k | 1.4% $ 23.9m | |
| Co-founder | 13.3yrs | US$784.86k | 1.4% $ 23.9m | |
| Independent Director | 6.2yrs | no data | no data | |
| Independent Director | 9.2yrs | no data | no data | |
| Director | less than a year | no data | no data | |
| Independent Director | 8.5yrs | US$269.53k | 0.078% $ 1.3m | |
| Independent Director | 9.2yrs | no data | no data | |
| Director | less than a year | no data | no data | |
| Independent Director | less than a year | US$448.63k | no data | |
| Director | less than a year | no data | 0.0056% $ 96.0k |
7.3yrs
Average Tenure
54yo
Average Age
Experienced Board: GDRX's board of directors are considered experienced (7.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 02:23 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
GoodRx Holdings, Inc. is covered by 28 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Vikram Kesavabhotla | Baird |
| Ishan Majumdar | Baptista Research |
| Michael Cherny | BofA Global Research |